Recently, Hybio Pharmaceutical announced a strategic investment partnership with Carbon Peptide Intelligence. Hybio Pharmaceutical has committed RMB 10 million in cash to subscribe for newly issued registered capital of Carbon Peptide Intelligence. Following this capital infusion, Hybio Pharmaceutical will own a 0.6623% equity stake, heralding a new chapter in their collaborative journey. This equity investment is poised to enhance the complementary strengths of both entities' core resources and infuse AI-driven innovation into Hybio Pharmaceutical's operations.

Previously, the two companies had already embarked on a joint venture with the implementation of the flagship project HY3003. Carbon Peptide Intelligence has successfully developed two pioneering pipelines: antimicrobial peptides and the peptide-drug conjugate iCPDC–001. Hybio Pharmaceutical, with its robust full-industry-chain infrastructure and exceptional industrial capacity, is set to offer comprehensive, end-to-end support for Carbon Peptide Intelligence's pivotal projects through its CRDMO (Contract Research, Development and Manufacturing Organization) model. The two firms are now intricately linked, establishing an "AI-driven R&D + industrial empowerment" paradigm. Moving forward, they are committed to deepening their partnership to propel China's AI-powered peptide innovation drugs onto the international stage.